An all-in-one AAV vector for cardiac-specific gene silencing by an adenine base editor

share:

Brief intro:

  • Author: Zhanzhao Liu, Luzi Yang, Yuhan Yang, Jiting Li, Zhan Chen, Congting Guo, Qianhao Guo, Qiuxuan Li, Yueshen Sun, Dongyu Zhao, Xiaomin Hu, Fei Gao and Yuxuan Guo
  • Journal: BioRxiv
  • Doi: https://www.doi.org/10.1101/2024.09.30.615742
  • Publication Date: 2024 Sep 30

Products/Services used in the paper

Quotation shows PackGene:We thank PackGene Biotech for AAV production and GenePlus for next-generation sequencing.

Research Field:cardiac gene therapy

AAV Serotype:AAV9

Targeted organ:ventricles

Animal or cell line strain:mice

Request Quote

Abstract

ABE editing outcomes are highly variable and unpredictable, depending on various factors. Therefore, the success rate of creating targeted A•T-to-G•C conversions using ABE is not high. But utilizing ABE to target RNA splicing sites for gene silencing has a higher success rate. Another challenge for base editing in the heart is that traditional ABE is too large in size, necessitating dual AAV delivery. Whether single AAV delivery can be achieved remains to be explored. In this study, we demonstrated how the diversity of Cas9 homologs and screening of sgRNAs can facilitate cardiac base editing. Single-AAV base editing outperformed dual-AAV systems in the heart, potentially benefiting from chromatin accessibility-guided sgRNA selection. These findings have important implications for the development of more effective and predictable base editing tools for cardiac gene therapy.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download